Rallybio

Rallybio Corp. is a clinical-stage biotechnology company focused on developing and commercializing therapies for severe and rare diseases. The company’s current pipeline centers on areas such as complement dysregulation, hematology, maternal-fetal health, and iron overload disorders. Its lead programs include RLYB116, a complement component 5 inhibitor being developed for diseases driven by complement dysregulation, and RLYB332, a preclinical antibody candidate for iron overload-related conditions. Rallybio also works on therapies for rare maternal-fetal disorders, reflecting its emphasis on areas with significant unmet medical need. Headquartered in New Haven, Connecticut, Rallybio operates as a focused drug development company in the biotechnology sector, advancing specialized treatments designed for patients with serious, underserved conditions.